Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: A randomized controlled study

Otolaryngology - Head and Neck Surgery (United States)

Volumn 150, Issue 6, 2014, Pages 983-990

  Marshak, Tal ^a,b   Steiner, Mariana ^c   Kaminer, Margalith ^a   Levy, Levana ^c   Shupak, Avi ^a,b,d  

^a Lin Medical Center   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c Department of Oncology Lin Medical Center ^*  (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cisplatin; Dexamethasone; Intratympanic; Ototoxicity; Prevention

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; NAVELBINE; PEMETREXED; TOPOTECAN; DEXAMETHASONE SODIUM PHOSPHATE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BARANY TEST; CANCER COMBINATION CHEMOTHERAPY; CENTRAL HEARING LOSS; CEREBROVASCULAR ACCIDENT; CISPLATIN INDUCED HEARING LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; IATROGENIC DISEASE; IMPEDANCE AUDIOMETRY; INJECTION PAIN; MALE; NEOPLASM; OTOTOXICITY; PROPHYLAXIS; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; TYMPANOMETRY; VERTIGO; WORD RECOGNITION; AGED; INJECTION SITE PAIN; OUTCOME ASSESSMENT; SPEECH AUDIOMETRY; TERTIARY CARE CENTER; AUDIOMETRY; CHEMICALLY INDUCED; HEARING LOSS; INTRATYMPANIC DRUG ADMINISTRATION; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CISPLATIN; DEXAMETHASONE; FEMALE; HEARING LOSS; HUMANS; INJECTION, INTRATYMPANIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84903552411     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599814524894     Document Type: Article

References (46)

1. Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg. 2007; 15:364-369.
2. Paksoy M, Ayduran E, Sanli A, Eken M, Aydin S, Oktay ZA. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol. 2011;28:615-621.
3. Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic Dexamethasone injections. Otol Neurotol. 2008;29:1005-1011.
4. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection clinical and experimental studies. Tohoku J Exp Med. 2009;219:177-186.
5. Schweitzer VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 1993;103:1-52.
6. Benedetti Panici P, Greggi S, Scambia G, et al. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Int J Gynecol Cancer. 1993;3:44-53.
7. Eianprapai P, Yamamoto N, Hiraumi H, et al. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients. Laryngoscope. 2012;122:1392-1396.
8. Konrad-Martin D, James KE, Gordon JS, et al. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010;21:301-314.
9. Schacht J, Talaska AE, Rybak L. Cisplatin and Aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec. 2012;295:1837-1850.
10. Shupak A, Tal D, Pratt H, Sharoni Z, Hochman A. Attenuation of cerebral oxygen toxicity by sound conditioning. Otol Neurotol. 2004;25:186-192.
11. Wang J, Ladrech S, Pujol R, Brabet P, Van De Water TR, Puel JL. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004;64:9217-9224.
12. Alam SA, Ikeda K, Oshima T, et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res. 2000; 141:28-38.
13. Clerici WJ, DiMartino DL, Prasad MR. Direct effect of reactive oxygen species on cochlear outer hair cells. Hear Res. 1995;84:30-40.
14. Tsukasaki N, Whitworth CA, Rybak LP. Acute changes in cochlear potentials due to cisplatin. Hear Res. 2000;149: 189-198.
15. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005;10:1313-1321.
16. Waissbluth S, Pitaro J, Daniel SJ. Gene therapy for cisplatininduced ototoxicity: a systematic review of in vitro and experimental animal studies. Otol Neurotol. 2012;33:302-310.
17. Giacca M. Introduction to gene therapy. In: Giacca M, ed. Gene Therapy. New York, NY: Springer-Verlag Italia; 2010:1-7.
18. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol. 2006;27:564-569.
19. Trune D, Canlon B. Corticosteroid therapy for hearing and balance disorders. Anat Rec. 2012;295:1928-1943.
20. Shimazaki T, Ichimiya I, Suzuki M, Mogi G. Localization of glucocorticoid receptors in the murine inner ear. Ann Otol Rhinol Laryngol. 2002;111:1133-1138.
21. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg. 2007;137:747-752.
22. Haake SM, Dinh CT, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hear Res. 2009;255:22-32.
23. Topdag M, Iseri M, Gelenli E, et al. Effect of intratympanic dexamethasone, memantine and piracetam on cellular apoptosis due to cisplatin ototoxicity. J Laryngol Otol. 2012;126:1091-1096.
24. Zhang C, Wenger T, Mattern J, et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors Cancer Biol Ther. 2007;6:278-287.
25. Herr I, Ucur E, Herzer K, et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003;63:3112-3120.
26. McCall AA, Swan EE, Borenstein JT, Sewell WF, Kujawa SG, McKenna MJ. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear. 2010;31:156-165.
27. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. Audiol Neurootol. 2009;14:350-360.
28. Plontke SK, Biegner T, Kammerer B, Delabar U, Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol. 2008;29:401-406.
29. Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146:S1-S35.
30. Shupak A, Tal D, Sharoni Z, Oren M, Ravid A, Pratt H. Otoacoustic emissions in early noise induced hearing loss. Otol Neurotol. 2007;28:745-752.
31. Biro K, Nozsek L, Prekopp P, et al. Characteristics and risk factors of cisplatin induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70:177-184.
32. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190-1195.
33. http://www.random.org/sequences.
34. American Speech-Language Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36:11-19.
35. Zuur CL, Simis YJW, Lansdaal PEM, et al. Audiometric patterns in otoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurotol. 2006;11:318-330.
36. Kumagami H, Terakado M, Takahashi H. Distribution of glucocorticoid receptors and 11a-hydroxysteroid dehydrogenase isoforms in the human inner ear. Otol Neurotol. 2013;34:151-157.
37. Yorgason JG, Luxford W, Kalinec F. In vitro and in vivo models of drug ototoxicity: studying the mechanisms of a clinical problem. Expert Opin Drug Metab Toxicol. 2011;7:1521-1534.
38. Underwood JL, Murphy CG, Chen J, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277:330-342.
39. Murphy D, Daniel SJ. Intratympanic Dexamrthasone to prevent Cisplatin ototoxicity: a guinea pig model. Otolaryngol Head Neck Surg. 2011;145:452-457.
40. Sha S-H, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res. 2001;155:1-8.
41. Shafik AG, Elkabarity RH, Thabet MT, Soliman NB, Kalleny NK. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris Nasus Larynx. 2013;40:51-60.
42. Laurell G, Andersson A, Engstrom B, Ehrsson H. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol. 1995;36:83-86.
43. Chandrasekhar SS, Rubinstein RY, Kwartler JA, et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg. 2000;122:521-528.
44. Wang X, Fernandez R, Dellamary L, et al. Pharmacokinetics of dexamethasone solution following intratympanic injection in guinea pig and sheep. Audiol Neurootol. 2011;16:233-241.
45. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362.
46. Jackson LE, Silverstein S. Chemical perfusion of the inner ear. Otolaryngol Clin N Am. 2002;35:639-653.